Q-omics provides the consensus-scored SPINK9 profile across patient tissues and cancer cell-line models. SPINK9 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SPINK9 is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, SPINK9 RNA expression shows 14,251 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, BLCA, and GBM as cancer lineages where SPINK9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPINK9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPINK9 survival associations across molecular data types. SPINK9 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPINK9 RNA expression–survival associations across cancer types. High SPINK9 expression shows unfavorable associations in COAD and KIRP, but favorable associations in BRCA, UCS, SARC and PAAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for SPINK9 RNA expression.
This table summarizes SPINK9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SPINK9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPINK9 shows lower tumor expression in BRCA, HNSC, KICH and UCEC and higher tumor expression in BLCA and KIRC. The BLCA box plot shows higher SPINK9 RNA expression in tumor versus normal tissue (log2 FC = +0.225, t-test p = .006).
This table shows molecular features associated with SPINK9 in patient tissues and cancer cell lines. In patient samples, SPINK9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPINK9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
